Tag: AAVance
Lysogene: the AAVance phase 2/3 study did not reach its primary efficacy endpoint
By Olivier Cheilan Published on 11/18/2022 at 6:20 p.m. (Boursier.com) —…
Lysogene Provides Update on Phase 2/3 AAVance Clinical Study with LYS-SAF302 Gene Therapy
By Claude Leguilloux Published on 06/03/2022 at 6:04 p.m. (Boursier.com) —…